GBIO241220C7500
- 0.00
- 0.000.00%
Generation Bio Newsroom
Generation Bio Co. Reports Q3 2024 Financials and Progress
Is Generation Bio (NASDAQ:GBIO) In A Good Position To Deliver On Growth Plans?
Earnings Update: Generation Bio Co. (NASDAQ:GBIO) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
CCORF Maintains Generation Bio(GBIO.US) With Buy Rating, Maintains Target Price $9
Promising Pipeline and Strong Financials Affirm Buy Rating for Generation Bio
Generation Bio GAAP EPS of -$0.23, Revenue of $7.55M
Hold Rating Maintained for Generation Bio Amid Technological Progress and Timeline Uncertainty
TD Cowen Maintains Generation Bio(GBIO.US) With Hold Rating
Generation Bio: Hold Rating Due to Positive Developments and Uncertain IND Timelines
Generation Bio Q3 EPS $(0.23) Beats $(0.28) Estimate, Sales $7.55M Beat $1.88M Estimate
Generation Bio | 10-Q: Q3 2024 Earnings Report
Generation Bio | 8-K: Generation Bio Reports Recent Business Highlights and Third Quarter 2024 Financial Results
Express News | Generation Bio Q3 Net Income USD -15.313 Million
Generation Bio 3Q Loss $15.3M >GBIO
Press Release: Generation Bio Reports Recent Business Highlights and Third Quarter 2024 Financial Results
Bullish Generation Bio Insiders Loaded Up On US$778.9k Of Stock
JMP Securities Maintains Generation Bio(GBIO.US) With Hold Rating
Needham Maintains Generation Bio(GBIO.US) With Buy Rating, Maintains Target Price $10
Generation Bio's Promising Advancements and Strategic Collaborations Drive Buy Rating
Generation Bio Says New Non-Human Primate Data Show Highly Selective In Vivo Delivery Of MRNA To T Cells With Cell-targeted Lipid Nanoparticle